Corporate Profile

At 60 Degrees Pharmaceuticals, Inc. (60P) we apply cutting-edge science and research to develop and commercialize new small molecule therapeutics for the prevention and treatment of infectious diseases. Our lead therapeutic, ARAKODA® (tafenoquine), is a malaria-preventative treatment marketed in the U.S. The 60P clinical pipeline includes development programs for treatments of COVID-19, fungal, tick-borne and viral diseases. Our team's top priority is completion of a Phase IIB clinical trial to prove the efficacy and safety of the ARAKODA regimen of Tafenoquine for treating COVID-19 in people with mild-moderate disease.

Recent Reports

More information is coming soon.

Quarterly Results


More events are coming soon.